Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria

TL;DR

This review explores how GLP-1 receptor agonists can protect the kidneys in type 2 diabetes patients by reducing albuminuria and improving overall health.

Contribution

The paper integrates clinical evidence to highlight personalized benefits of GLP-1RAs on kidney outcomes and suggests future research directions.

Findings

GLP-1RAs reduce albuminuria and slow diabetic kidney disease progression.

These drugs offer cardiovascular and renal benefits by improving glycemic control and reducing inflammation.

Individual patient profiles influence the effectiveness of GLP-1RAs in managing kidney outcomes.

Abstract

The aim of this narrative review is to critically assess the renoprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in managing albuminuria among patients with type 2 diabetes mellitus within the framework of personalized medicine. By integrating current evidence from clinical trials and meta-analyses, the review highlights how GLP-1RAs not only enhance glycemic control but also reduce blood pressure, induce weight loss, and mitigate inflammatory responses. While these given factors may vary according to individual patient profiles, they also collectively contribute to slowing the progression of diabetic kidney disease (DKD). Additionally, the discussion emphasizes the dual cardiovascular and renal benefits from these agents, underscoring their role in reducing albuminuria and preserving renal function. The review also identifies gaps in knowledge, suggesting future research directions for optimizing patient selection and treatment regimens to maximize therapeutic benefits.

Figures